Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10301 - 10325 of 12433 in total
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid ... )-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of
Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
Investigational
Matched Description: … on Vascular Function - the Role of Endothelin). ... Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation …
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. ... This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder …
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase ... VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions …
An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Investigational
Matched Description: … Some indications of efficacy were demonstrated. ... its ability to mimic the function of glutathione peroxidase. ... BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of
AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.
Investigational
Matched Description: … mechanism of action as rimonabant. ... AVE-1625 is also being developed for the treatment of Alzheimer disease. ... AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same …
Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136. This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.
Investigational
Matched Description: … [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity ... Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation …
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids...
Investigational
Matched Description: … The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only ... on the disease causing components of the immune system. ... Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. …
Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima). Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations and triggering cell...
Experimental
Matched Description: … ] and triggering cell death and blocking cell proliferation of glioblastoma cell lines [A27194]. ... Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima ... Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence …
ORG-34517 is currently under investigation by Organon for the treatment of depression. It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Investigational
Matched Description: … etc, in which the activity of metabolites corticosterone and cortisol is high. ... ORG-34517 is currently under investigation by Organon for the treatment of depression. ... It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma …
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Investigational
Matched Description: … DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of
Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis).
Investigational
Matched Description: … the Treatment of Idiopathic Pulmonary Fibrosis). ... Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in …
Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)).
Investigational
Matched Description: … of Postoperative Crohn's Disease (CD)). ... Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence …
Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
Investigational
Matched Description: … Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 …
VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational
Matched Description: … for the treatment of peripheral vascular disease. ... VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 …
Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
Investigational
Matched Description: … Melanoma Stage IV After Failure of Prior Therapy). ... Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant …
Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
Investigational
Matched Description: … Leukemia, and Squamous Cell Carcinoma of the Oral Cavity. ... Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic …
Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).
Investigational
Matched Description: … Impairment on the Pharmacokinetics of AL-335). ... Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal …
Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Investigational
Matched Description: … on Pharmacokinetics of Atorvastatin in Healthy Volunteers). ... Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 …
Ribaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).
Investigational
Matched Description: … of c.diff in Patients With a LRTI). ... Ribaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention …
Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
Investigational
Matched Description: … Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis). ... Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in …
A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [PubChem]
Experimental
Matched Description: … Obtained from the partial hydrolysis of cellulose. [PubChem] ... A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. …
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Investigational
Matched Description: … of Renal Anemia in Non-dialysis Subjects). ... Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction …
A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is...
Experimental
Matched Description: … preparations that have been used for treatment of pain and inflammation of the mouth. ... Its antidiuretic effects are less than those of vasopressin. ... non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of
Displaying drugs 10301 - 10325 of 12433 in total